Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 1 Feb 2017

Yang Xue, Li Jiao, Li Xiaoyi, Liang Zhiyong, Gao Wen, Liang Jun, Cheng Shujun, Lin Yansong

Abstract excerpt

Telomerase reverse transcriptase (TERT) promoter mutation has been reported to be associated with aggressive characteristics in differentiated thyroid cancer (DTC). This study examined the status of TERT mutation in distant metastatic DTC and evaluated the correlation between TERT mutation and radioiodine uptake, as well as that between TERT mutation and therapy response. METHODS: TERT promoter and B-Raf...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Iodine Radioisotopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Proto-Oncogene Mas

Share to Radiation Tolerance

Share to Telomerase

Share to Thyroid Neoplasms

Share to Treatment Failure

Source

Identifiers

PMID: 27493271
DOI: 10.2967/jnumed.116.180240

Genes

TERT
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.PMID 27493271Read ↗

TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.Semantic proximity Read ↗

TERT Promoter Mutations Contribute to Adverse Clinical Outcomes and Poor Prognosis in Radioiodine Refractory Differentiated Thyroid CancerSemantic proximity Read ↗

Effect of BRAFV600E and TERT Promoter Mutations on Thyroglobulin Response in Patients With Distant-Metastatic Differentiated Thyroid Cancer.Semantic proximity Read ↗

The Correlation Between the Presence of BRAFV600E and TERT Promoter Mutation and the Response to Treatment with Iodine 131 in Differentiated Thyroid Cancer Patients.Semantic proximity Read ↗

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.Semantic proximity Read ↗

Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.Semantic proximity Read ↗

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.Semantic proximity Read ↗

Clinical Outcome and Prognosis of Differentiated Thyroid Carcinoma with Distant MetastasisSemantic proximity Read ↗

Association between clinical and pathological factors and risk of radioiodine refractory in patients with differentiated thyroid carcinoma.Semantic proximity Read ↗

Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.Semantic proximity Read ↗

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.